NL
DE
Less damage to organs and a greater chance of survival after having a heart attack. That's what Radboudumc spin-off CardiacBooster is aiming to accomplish.
Related news items
Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders
31 March 2023 Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. read moreAftermovie Investment Day 2022 and a new date for 2023!
31 March 2023Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read more
Radboudumc Investment Day 2022
31 March 2023Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!
read moreJoining forces increases innovation Janssen and Radboud
31 March 2023Dr. Eng Kinga Matuła (KM), specialist in single-cell multi-omics and Jeroen Van Houdt (JH), Omics group leader at Janssen Pharmaceutica, answer three pressing questions about the successful collaboration in the single-cell technology project.
read more
Saving lives with a small pump inside the heart CardiacBooster
15 June 2021 Less damage to organs and a greater chance of survival after having a heart attack. That's what Radboudumc spin-off CardiacBooster is aiming to accomplish. read more
